Viridian Therapeutics Inc. (VRDN)
$22.92
$-0.04
(-0.17%)
As on 04-Sep-2026 16:09EDT
Market cap
$2,597 Mln
Revenue (TTM)
$71 Mln
P/E Ratio
--
P/B Ratio
4.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.2
-
Debt to Equity
0.4
-
Book Value
$--
-
EPS
$-4
-
Face value
--
-
Shares outstanding
113,292,269
10 Years Aggregate
CFO
$-469.78 Mln
EBITDA
$-610.70 Mln
Net Profit
$-687.11 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Viridian Therapeutics (VRDN)
| -26.3 | 18.7 | 40.2 | 17.7 | 6.2 | 13.4 | -15.0 |
|
BSE Sensex*
| -10.6 | -3.6 | 1.9 | -6.2 | 4.5 | 5.4 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Viridian Therapeutics (VRDN)
| 62.3 | -11.9 | -25.4 | 47.7 | 20.2 | 128.5 | -84.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Viridian Therapeutics (VRDN)
|
22.9 | 2,596.7 | 71.1 | -387.0 | -517.4 | -55.9 | -- | 4.6 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Viridian Therapeutics (VRDN)
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized... monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts. Read more
-
CEO, President & Director
Mr. Stephen F. Mahoney J.D., MBA
-
CEO, President & Director
Mr. Stephen F. Mahoney J.D., MBA
-
Headquarters
Waltham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Viridian Therapeutics (VRDN)
What is the current share price of Viridian Therapeutics Inc (VRDN) Today?
The share price of Viridian Therapeutics Inc (VRDN) is $22.92 (NASDAQ) as of 04-Sep-2026 16:09 EDT. Viridian Therapeutics Inc (VRDN) has given a return of 6.25% in the last 3 years.
What is the current PB & PE ratio of Viridian Therapeutics Inc (VRDN)?
Since, TTM earnings of Viridian Therapeutics Inc (VRDN) is negative, P/E ratio is not available.
The P/B ratio of Viridian Therapeutics Inc (VRDN) is 4.61 times as on 04-Sep-2026, a 14 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-7.70 |
3.65 |
2024 |
-5.68 |
2.28 |
2023 |
-4.55 |
2.45 |
2022 |
-9.12 |
3.00 |
2021 |
-2.78 |
1.18 |
What is the 52 Week High and Low of Viridian Therapeutics Inc (VRDN)?
The 52-week high and low of Viridian Therapeutics Inc (VRDN) are Rs 34.18 and Rs 13.19 as of 08-Sep-2026.
What is the market cap of Viridian Therapeutics Inc (VRDN)?
Viridian Therapeutics Inc (VRDN) has a market capitalisation of $ 2,597 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Viridian Therapeutics Inc (VRDN)?
Before investing in Viridian Therapeutics Inc (VRDN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.